Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework

M. L. Bellows, M. S. Taylor, P. A. Cole, L. Shen, R. F. Siliciano, H. K. Fung, C. A. Floudas

Research output: Contribution to journalArticlepeer-review

Abstract

A new (to our knowledge) de novo design framework with a ranking metric based on approximate binding affinity calculations is introduced and applied to the discovery of what we believe are novel HIV-1 entry inhibitors. The framework consists of two stages: a sequence selection stage and a validation stage. The sequence selection stage produces a rankordered list of amino-acid sequences by solving an integer programming sequence selection model. The validation stage consists of fold specificity and approximate binding affinity calculations. The designed peptidic inhibitors are 12-amino-acidslong and target the hydrophobic core of gp41. A number of the best-predicted sequences were synthesized and their inhibition of HIV-1 was tested in cell culture. All peptides examined showed inhibitory activity when compared with no drug present, and the novel peptide sequences outperformed the native template sequence used for the design. The best sequence showed micromolar inhibition, which is a 3-15-fold improvement over the native sequence, depending on the donor. In addition, the best sequence equally inhibited wild-type and Enfuvirtide-resistant virus strains.

Original languageEnglish (US)
Pages (from-to)3445-3453
Number of pages9
JournalBiophysical journal
Volume99
Issue number10
DOIs
StatePublished - Nov 17 2010

ASJC Scopus subject areas

  • Biophysics

Fingerprint Dive into the research topics of 'Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework'. Together they form a unique fingerprint.

Cite this